HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea · Delayed Price · Currency is KRW 6,510.00
-90.00 (-1.36%)
Sep 17, 2026, 3:30 PM KST
HLB Pharmaceutical Revenue
HLB Pharmaceutical had revenue of 62.28B KRW in the quarter ending June 30, 2026, with 32.73% growth. This brings the company's revenue in the last twelve months to 251.95B, up 68.61% year-over-year. In the year 2025, HLB Pharmaceutical had annual revenue of 205.58B with 49.97% growth.
Revenue (ttm)
251.95B
Revenue Growth
+68.61%
P/S Ratio
0.85
Revenue / Employee
1.28B
Employees
197
Market Cap
213.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 205.58B | 68.50B | 49.97% |
| Dec 31, 2024 | 137.08B | 100.98B | 279.73% |
| Dec 31, 2019 | 36.10B | 15.56B | 75.75% |
| Dec 31, 2018 | 20.54B | 4.98B | 32.03% |
| Dec 31, 2017 | 15.56B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Suheung | 765.90B |
| Huons | 607.75B |
| Samjin Pharmaceuticals | 274.03B |
| Whan In Pharm | 273.47B |
| Korea United Pharm | 161.44B |
| Yungjin Pharm. | 158.79B |
| REYON Pharmaceutical | 143.37B |